- Home
- USAS vs VIGL Comparison
USAS vs VIGL Comparison
Compare USAS & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAS
- VIGL
- Stock Information
- Founded
- USAS 1998
- VIGL 2020
- Country
- USAS Canada
- VIGL United States
- Employees
- USAS N/A
- VIGL N/A
- Industry
- USAS Metal Mining
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- USAS Basic Materials
- VIGL Health Care
- Exchange
- USAS Nasdaq
- VIGL Nasdaq
- Market Cap
- USAS 122.4M
- VIGL 141.5M
- IPO Year
- USAS N/A
- VIGL 2022
- Fundamental
- Price
- USAS $0.38
- VIGL $3.00
- Analyst Decision
- USAS Strong Buy
- VIGL Buy
- Analyst Count
- USAS 1
- VIGL 5
- Target Price
- USAS $0.80
- VIGL $16.80
- AVG Volume (30 Days)
- USAS 1.5M
- VIGL 51.3K
- Earning Date
- USAS 11-07-2024
- VIGL 11-07-2024
- Dividend Yield
- USAS N/A
- VIGL N/A
- EPS Growth
- USAS N/A
- VIGL N/A
- EPS
- USAS N/A
- VIGL N/A
- Revenue
- USAS $97,123,000.00
- VIGL N/A
- Revenue This Year
- USAS $25.05
- VIGL N/A
- Revenue Next Year
- USAS $35.97
- VIGL N/A
- P/E Ratio
- USAS N/A
- VIGL N/A
- Revenue Growth
- USAS 14.33
- VIGL N/A
- 52 Week Low
- USAS $0.20
- VIGL $2.47
- 52 Week High
- USAS $0.54
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- USAS 45.04
- VIGL 32.87
- Support Level
- USAS $0.32
- VIGL $2.89
- Resistance Level
- USAS $0.42
- VIGL $3.26
- Average True Range (ATR)
- USAS 0.04
- VIGL 0.22
- MACD
- USAS -0.01
- VIGL -0.08
- Stochastic Oscillator
- USAS 37.38
- VIGL 9.40
About USAS Americas Gold and Silver Corporation no par value
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets are The Cosala operations, The Galena Complex, and Relief Canyon. The company also holds interests in the San Felipe Development Project located in Sonora, Mexico. It has geographic focus is the Western Hemisphere, particularly the United States and Mexico.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.